Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin
Optical Spectroscopy for Non-invasive Diagnosis of Melanoma and Assessment of Impact of UV Exposure on Skin
Status: Enrolling
Updated:  3/10/2010
UPMC Shadyside Place - Dermatology Unit
mi
from
Pittsburgh, PA
Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin
Optical Spectroscopy for Non-invasive Diagnosis of Melanoma and Assessment of Impact of UV Exposure on Skin
Status: Enrolling
Updated: 3/10/2010
UPMC Shadyside Place - Dermatology Unit
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging
Status: Enrolling
Updated:  3/25/2010
GE Healthcare Office
mi
from
Princeton, NJ
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging
Status: Enrolling
Updated: 3/25/2010
GE Healthcare Office
mi
from
Princeton, NJ
Click here to add this to my saved trials
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Phase I Study of Active Immunotherapy of Metastatic Melanoma With Mature Autologous Dendritic Cells Transfected With Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing
Status: Enrolling
Updated:  9/21/2010
Duke Univ Med Ctr
mi
from
Durham, NC
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Phase I Study of Active Immunotherapy of Metastatic Melanoma With Mature Autologous Dendritic Cells Transfected With Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing
Status: Enrolling
Updated: 9/21/2010
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
Phase 1 Study of Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  10/6/2010
Duke Univ Med Ctr
mi
from
Durham, NC
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
Phase 1 Study of Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 10/6/2010
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy (Phase 1b)
Status: Enrolling
Updated:  10/11/2010
Chao Family Comprehensive Cancer Center, University of California, Irvine
mi
from
Orange, CA
Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy (Phase 1b)
Status: Enrolling
Updated: 10/11/2010
Chao Family Comprehensive Cancer Center, University of California, Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery
Fast Absorbing Gut Suture Versus Cyanoacrylate Tissue Adhesive in the Epidermal Closure of Linear Repairs Following Mohs Micrographic Surgery
Status: Enrolling
Updated:  2/15/2011
Yale Dermatologic Surgery
mi
from
New Haven, CT
Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery
Fast Absorbing Gut Suture Versus Cyanoacrylate Tissue Adhesive in the Epidermal Closure of Linear Repairs Following Mohs Micrographic Surgery
Status: Enrolling
Updated: 2/15/2011
Yale Dermatologic Surgery
mi
from
New Haven, CT
Click here to add this to my saved trials
Melanoma Biomarker Study
CXCL1 Biomarker Study in Metastatic Melanoma
Status: Enrolling
Updated:  7/19/2011
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Melanoma Biomarker Study
CXCL1 Biomarker Study in Metastatic Melanoma
Status: Enrolling
Updated: 7/19/2011
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma
Status: Enrolling
Updated:  8/8/2011
New England Retina Associates
mi
from
Hamden, CT
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma
Status: Enrolling
Updated: 8/8/2011
New England Retina Associates
mi
from
Hamden, CT
Click here to add this to my saved trials
Feasibility and Functionality of fPAM Imaging in Melanoma
Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Characterization and Early Diagnosis of Melanoma
Status: Enrolling
Updated:  8/16/2011
Washington University and Washington University School of Medicine
mi
from
St. Louis, MO
Feasibility and Functionality of fPAM Imaging in Melanoma
Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Characterization and Early Diagnosis of Melanoma
Status: Enrolling
Updated: 8/16/2011
Washington University and Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Status: Enrolling
Updated:  10/5/2011
Highland Springs Medical Plaza
mi
from
Beaumont, CA
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Status: Enrolling
Updated: 10/5/2011
Highland Springs Medical Plaza
mi
from
Beaumont, CA
Click here to add this to my saved trials
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Status: Enrolling
Updated:  10/5/2011
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Status: Enrolling
Updated: 10/5/2011
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer
Status: Enrolling
Updated:  10/31/2011
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer
Status: Enrolling
Updated: 10/31/2011
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
Status: Enrolling
Updated:  11/4/2011
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
Status: Enrolling
Updated: 11/4/2011
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1
Status: Enrolling
Updated:  1/3/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1
Status: Enrolling
Updated: 1/3/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1
Status: Enrolling
Updated:  1/3/2012
New York University (NYU) Cancer Center
mi
from
New York, NY
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1
Status: Enrolling
Updated: 1/3/2012
New York University (NYU) Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
IMCgp100 in Advanced Unresectable Melanoma
A Phase 0, Exploratory Study of the Pharmacodynamics of a Single Intratumoral Dose of IMCgp100, a Monoclonal Receptor Anti-CD3 scFv Fusion Protein, in Subjects With Advanced Unresectable Melanoma
Status: Enrolling
Updated:  2/7/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
IMCgp100 in Advanced Unresectable Melanoma
A Phase 0, Exploratory Study of the Pharmacodynamics of a Single Intratumoral Dose of IMCgp100, a Monoclonal Receptor Anti-CD3 scFv Fusion Protein, in Subjects With Advanced Unresectable Melanoma
Status: Enrolling
Updated: 2/7/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer
Use of the Epidermal Expansion System to Harvest and Place Suction Blister Epidermal Grafts on Wounds in Patients After Mohs or Excisional Surgery for Skin Cancer
Status: Enrolling
Updated:  2/21/2012
DuPage Medical Group
mi
from
Naperville, IL
Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer
Use of the Epidermal Expansion System to Harvest and Place Suction Blister Epidermal Grafts on Wounds in Patients After Mohs or Excisional Surgery for Skin Cancer
Status: Enrolling
Updated: 2/21/2012
DuPage Medical Group
mi
from
Naperville, IL
Click here to add this to my saved trials
Vismodegib for Treatment of Basal Cell Carcinoma
Placebo-controlled, Double Blind Study to Assess Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery (MMS)
Status: Enrolling
Updated:  4/17/2012
Faculty Medical Offices
mi
from
Loma Linda, CA
Vismodegib for Treatment of Basal Cell Carcinoma
Placebo-controlled, Double Blind Study to Assess Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery (MMS)
Status: Enrolling
Updated: 4/17/2012
Faculty Medical Offices
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
A Phase II Trial of Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Status: Enrolling
Updated:  4/18/2012
The Angeles Clinic and Research Institute
mi
from
Santa Monica, CA
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
A Phase II Trial of Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Status: Enrolling
Updated: 4/18/2012
The Angeles Clinic and Research Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
A Phase II Trial of Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Status: Enrolling
Updated:  4/18/2012
Saint Mary's Medical Center, 6th Floor
mi
from
San Francisco, CA
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
A Phase II Trial of Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Status: Enrolling
Updated: 4/18/2012
Saint Mary's Medical Center, 6th Floor
mi
from
San Francisco, CA
Click here to add this to my saved trials
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
A Phase II Trial of Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Status: Enrolling
Updated:  4/18/2012
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
A Phase II Trial of Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
Status: Enrolling
Updated: 4/18/2012
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Ph I/II Ipilimumab Vemurafenib Combo
A Phase I/II Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma
Status: Enrolling
Updated:  4/30/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Ph I/II Ipilimumab Vemurafenib Combo
A Phase I/II Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma
Status: Enrolling
Updated: 4/30/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ph I/II Ipilimumab Vemurafenib Combo
A Phase I/II Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma
Status: Enrolling
Updated:  4/30/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Ph I/II Ipilimumab Vemurafenib Combo
A Phase I/II Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma
Status: Enrolling
Updated: 4/30/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Ph I/II Ipilimumab Vemurafenib Combo
A Phase I/II Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma
Status: Enrolling
Updated:  4/30/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Ph I/II Ipilimumab Vemurafenib Combo
A Phase I/II Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma
Status: Enrolling
Updated: 4/30/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
Status: Enrolling
Updated:  5/2/2012
Dr. Steven O'Day
mi
from
Los Angeles, CA
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
Status: Enrolling
Updated: 5/2/2012
Dr. Steven O'Day
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
Status: Enrolling
Updated:  5/2/2012
Mt Sinai Medical Center
mi
from
Miami Beach, FL
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
Status: Enrolling
Updated: 5/2/2012
Mt Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma
Status: Enrolling
Updated:  5/2/2012
Jose Lutzky, MD
mi
from
Miami Beach, FL
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma
Status: Enrolling
Updated: 5/2/2012
Jose Lutzky, MD
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma
Status: Enrolling
Updated:  5/2/2012
David Lawson, MD
mi
from
Atlanta, GA
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma
Status: Enrolling
Updated: 5/2/2012
David Lawson, MD
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Phoenix, AZ
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Santa Clara, CA
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Decatur, GA
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Park Ridge, IL
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Louisville, KY
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Dallas, TX
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated:  5/8/2012
Clinical Research Facility
mi
from
Milwaukee, WI
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
A Phase II, Multicenter, Open-Label, Three-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)
Status: Enrolling
Updated: 5/8/2012
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Status: Enrolling
Updated:  6/29/2012
University of New Mexico
mi
from
Albuquerque, NM
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Status: Enrolling
Updated: 6/29/2012
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Status: Enrolling
Updated:  6/29/2012
Lovelace Women's Hospial
mi
from
Albuquerque, NM
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Status: Enrolling
Updated: 6/29/2012
Lovelace Women's Hospial
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Status: Enrolling
Updated:  7/5/2012
Stanford University School of Medicine
mi
from
Stanford, CA
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Status: Enrolling
Updated: 7/5/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Identifying Skin Biopsy Sites
Pilot Study of Skin Biopsy Sites: A Consensus Approach Based on Patient and Physician Interviews
Status: Enrolling
Updated:  7/9/2012
Northwestern University Dermatology
mi
from
Chicago, IL
Identifying Skin Biopsy Sites
Pilot Study of Skin Biopsy Sites: A Consensus Approach Based on Patient and Physician Interviews
Status: Enrolling
Updated: 7/9/2012
Northwestern University Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/19/2012
Cancer Therapy and Research Center at UTHSCSA
mi
from
San Antonio, TX
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/19/2012
Cancer Therapy and Research Center at UTHSCSA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase II Trial of Mitogen Activated Protein (MAP) Kinase Inhibition With AZD6244 and MK-2206 (Akt Inhibitor) in Patients With Relapsed (BRAF) V600E Mutant Advanced Melanoma
Randomized Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600E Mutant Advanced Melanoma Who Have Previously Failed Prior Therapy With a Selective BRAF Inhibitor (PLX4032/RG7204 or GSK2118436)
Status: Enrolling
Updated:  7/21/2012
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Phase II Trial of Mitogen Activated Protein (MAP) Kinase Inhibition With AZD6244 and MK-2206 (Akt Inhibitor) in Patients With Relapsed (BRAF) V600E Mutant Advanced Melanoma
Randomized Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600E Mutant Advanced Melanoma Who Have Previously Failed Prior Therapy With a Selective BRAF Inhibitor (PLX4032/RG7204 or GSK2118436)
Status: Enrolling
Updated: 7/21/2012
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase II Trial of Mitogen Activated Protein (MAP) Kinase Inhibition With AZD6244 and MK-2206 (Akt Inhibitor) in Patients With Relapsed (BRAF) V600E Mutant Advanced Melanoma
Randomized Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600E Mutant Advanced Melanoma Who Have Previously Failed Prior Therapy With a Selective BRAF Inhibitor (PLX4032/RG7204 or GSK2118436)
Status: Enrolling
Updated:  7/21/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Phase II Trial of Mitogen Activated Protein (MAP) Kinase Inhibition With AZD6244 and MK-2206 (Akt Inhibitor) in Patients With Relapsed (BRAF) V600E Mutant Advanced Melanoma
Randomized Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600E Mutant Advanced Melanoma Who Have Previously Failed Prior Therapy With a Selective BRAF Inhibitor (PLX4032/RG7204 or GSK2118436)
Status: Enrolling
Updated: 7/21/2012
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase II Trial of Mitogen Activated Protein (MAP) Kinase Inhibition With AZD6244 and MK-2206 (Akt Inhibitor) in Patients With Relapsed (BRAF) V600E Mutant Advanced Melanoma
Randomized Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600E Mutant Advanced Melanoma Who Have Previously Failed Prior Therapy With a Selective BRAF Inhibitor (PLX4032/RG7204 or GSK2118436)
Status: Enrolling
Updated:  7/21/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Phase II Trial of Mitogen Activated Protein (MAP) Kinase Inhibition With AZD6244 and MK-2206 (Akt Inhibitor) in Patients With Relapsed (BRAF) V600E Mutant Advanced Melanoma
Randomized Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600E Mutant Advanced Melanoma Who Have Previously Failed Prior Therapy With a Selective BRAF Inhibitor (PLX4032/RG7204 or GSK2118436)
Status: Enrolling
Updated: 7/21/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
Prognostication of Uveal Melanoma by Fine Needle Aspiration (FNA) and Fluorescence in Situ Hybridization (FlSH)
Status: Enrolling
Updated:  8/2/2012
Cleveland Clinic - Cole Eye Institute
mi
from
Cleveland, OH
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
Prognostication of Uveal Melanoma by Fine Needle Aspiration (FNA) and Fluorescence in Situ Hybridization (FlSH)
Status: Enrolling
Updated: 8/2/2012
Cleveland Clinic - Cole Eye Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  9/18/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 9/18/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  9/18/2012
Providence Portland Medical Center
mi
from
Portland, OR
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 9/18/2012
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/4/2012
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/4/2012
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials